Your session is about to expire
← Back to Search
Genetic testing for Castleman's Disease
N/A
Waitlist Available
Led By Sudipto Mukherjee, MD, PhD
Research Sponsored by Case Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months from last participant accrued
Awards & highlights
Study Summary
This trial will use WES to learn more about rare blood diseases and identify possible treatments.
Eligible Conditions
- Castleman's Disease
- Langerhans Cell Histiocytosis
- Non-Langerhans-Cell Histiocytosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months from last participant accrued
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months from last participant accrued
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of genomic analyses yielding genetic aberrations
Secondary outcome measures
Completion rates of genetic counseling for germline mutations
Proportion of genomic analyses yielding actionable genetic aberrations
Proportion of genomic analyses yielding germline genetic aberrations
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Genomic analysisExperimental Treatment1 Intervention
When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Genetic testing
2017
N/A
~5890
Find a Location
Who is running the clinical trial?
Case Comprehensive Cancer CenterLead Sponsor
456 Previous Clinical Trials
31,978 Total Patients Enrolled
Sudipto Mukherjee, MD, PhDPrincipal InvestigatorCleveland Clinic, Case Comprehensive Cancer Center
3 Previous Clinical Trials
74 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger